Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.98 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2462234 | 1.00 | ADORA3 (0.98) | ADORA3P2RX3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL28769810 | 0.97 | ADORA3 (0.93) | ADORA3P2RX3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL2463062 | 0.93 | ADORA3 (0.85) | ADORA3ADORA2ASLC29A1 | |
| SCHEMBL2463074 | 0.93 | ADORA3 (0.85) | ADORA3ADORA2ASLC29A1 | |
| SCHEMBL11876601 | 0.91 | ADORA3 (0.82) | ADORA3ADORA2A | |
| SCHEMBL11876564 | 0.91 | ADORA3 (0.82) | ADORA3ADORA2A | |
| SCHEMBL8861545 | 0.90 | ADORA3 (0.83) | ADORA3P2RX3ADORA2A | |
| SCHEMBL8861539 | 0.90 | ADORA3 (0.83) | ADORA3P2RX3ADORA2A | |
| SCHEMBL11881369 | 0.89 | ADORA3 (0.80) | ADORA3ADORA2A | |
| SCHEMBL2458421 | 0.89 | ADORA3 (0.79) | ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364086-B1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GLSYNTHESIS INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-8575127-B2 | Antithrombotic diadenosine tetraphosphates and related analogs | GLSYNTHESIS INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110257252-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GLSYNTHESIS INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-2364086-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | Glsynthesis Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010059215-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GLSYNTHESIS INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| US-5654285-A | ADP and ATP analogues, process for making and administration to inhibit ADP-induced platelet aggregation | ASTRA PHARMACEUTICALS LIMITED (GB) | 1997-08-05 | — | — | US | disclosed |
| EP-0508687-B1 | ATP analogues | FISONS PLC (GB) | 1995-09-13 | — | — | EP | disclosed |
| EP-0579643-A1 | ATP ANALOGUES | FISONS plc (GB) | 1994-01-26 | — | — | EP | disclosed |
| WO-1992017488-A1 | ATP ANALOGUES | FISONS PLC (GB) | 1992-10-15 | — | — | WO | disclosed |
| EP-0508687-A1 | ATP analogues | Astra Pharmaceuticals Limited (GB) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257252-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GP6, P2RY6, PFKP | ADORA3 59/4885P2RX3 53/4885ADORA2A 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.